Increased serum levels of the pro-inflammatory cytokine interleukin-6 (IL-6), usually secreted by CCA cells [86], were reported in patients with bile duct cancer compared to healthy individuals, harboring great sensitivity (73%) and specificity (92%) values and also being proposed as a potential marker for therapy monitoring [87]. This evidence concerns the gene IL6 and bile duct cancer.